4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-18-050356
Chief Financial Officer sold 45,000 shares at an average $19.34 ($870,200)
- Chief Financial Officer acquired 45,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Option exercise | +25,000 | $2.62 | $65,500 | 335,815 | D: show line 1 in the form |
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Option exercise | +20,000 | $4.75 | $95,000 | 355,815 | D: show line 2 in the form |
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Sale | −25,000 | $18.00 | $450,000 | 330,815 | D: show line 3 in the form |
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Sale | −20,000 | $21.01 | $420,200 | 310,815 | D: show line 4 in the form |
| Open-market sales · 45,000 sh · avg $19.34 · $870,200 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Option exercise · Stock Option (right to buy) | −25,000 | 263,000 | D: show line 5 in the form | |||||
| Myszkowski Kenneth Allen Chief Financial Officer | 2018-09-06 | Option exercise · Stock Option (right to buy) | −20,000 | 243,000 | D: show line 6 in the form |
Loading xslF345X03/doc4.xml…